


agent comprising a sequence [consisting] of at least three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I



[in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group, or is absent;]

wherein  $R^1$  is selected from the group consisting of Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc, or  $R^1$  is absent;

$R^2$  is selected from the group consisting of Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer and azaTyr;

$R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

$R^6$  is selected from the group consisting of His, Arg or 6-NH<sub>2</sub>-Phe;

$R^7$  is selected from the group consisting of Pro or Ala; and

$R^8$  is selected from the group consisting of Phe, Phe(Br), Ile, Tyr, or is absent,

and wherein the active agent is not SEQ ID NO:1 or SEQ ID NO:19.

A3  
cm, it

A3  
concl'd.  
up transverse

2. (Amended) The method of claim 1 wherein the active agent comprises a sequence [is] selected from the group consisting of angiotensinogen, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, (SEQ ID NO:9), SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, [SEQ ID NO:19] SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39.

Please add the following new claims:

- A4  
cm.t
31. The method of claim 1 wherein the active agent comprises a sequence of at least four contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.
32. The method of claim 1 wherein the active agent comprises a sequence of at least five contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.
33. The method of claim 1 wherein the active agent comprises a sequence of at least six contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.
34. The method of claim 1 wherein the active agent comprises a sequence of at least seven contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.
35. The method of claim 1 wherein the active agent consists essentially of a sequence of at least three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.

36. The method of claim 1 wherein the active agent consists essentially of a sequence of at least four contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.

37. The method of claim 1 wherein the active agent consists essentially of a sequence of at least five contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.

38. The method of claim 1 wherein the active agent consists essentially of a sequence of at least six contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.

39. The method of claim 1 wherein the active agent consists essentially of a sequence of at least seven contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I.

40. The method of claim 1 wherein the contacting occurs in vivo and a dosage of active agent is between about 0.1 ng/kg and about 10.0 mg/kg.

41. The method of claim 1 wherein the contacting occurs in vitro and a dosage of active agent is between about 0.1 ng/ml and about 10.0 mg/ml.

42. The method of claim 1 further comprising contacting the erythroid progenitor cells with an amount effective to augment erythropoiesis of erythropoietin.

43. The method of claim 1, wherein the method is used to treat anemia associated with a condition selected from the group consisting of chronic renal failure, end-stage renal disease, renal transplantation, cancer, acquired immune deficiency syndrome, chemotherapy, radiotherapy, and bone marrow transplantation.